Thermo Fisher Scientific Q2 Earnings Call Highlights

Thermo Fisher posted stronger-than-expected Q2 2026 results, with revenue up 10% to $11.99 billion and adjusted EPS up 13% to $6.03, driven by broad-based growth and recent acquisitions. The company said customer activity improved across end markets, especially in pharma and biotech, while all four business segments contributed to growth and margins generally expanded. Thermo Fisher raised its full-year outlook, now expecting 2026 revenue of $47.4 billion to $48.1 billion and adjusted EPS of $24.93 to $25.33, while also noting continued benefits from acquisitions and capital returns.

Thermo Fisher Scientific NYSE: TMO reported stronger-than-expected second-quarter 2026 results and raised its full-year outlook, citing improving customer activity across end markets, broad-based growth and contributions from recent acquisitions. Chairman and Chief Executive Officer Marc Casper said the company delivered an “outstanding quarter,” with revenue rising 10% to $11.99 billion. Adjusted operating income increased 15% to $2.73 billion, while adjusted operating margin expanded 90 basis points to 22.8%. Adjusted earnings per share grew 13% to $6.03.

Chief Financial Officer Jim Meyer said the results were meaningfully ahead of the company’s prior assumptions. Revenue was about $300 million above previous guidance, helped by stronger organic growth, acquisitions and foreign exchange. Adjusted EPS was $0.30 ahead of prior guidance, which Meyer attributed to revenue pull-through, cost productivity and acquisition performance, including Clario. Customer Activity Strengthens Across End Markets Thermo Fisher reported 5% organic revenue growth in the quarter. Casper said customer activity continued to improve across the company’s end markets, with particular strength in pharma and biotech, the company’s largest end market. In pharma and biotech, revenue grew in the mid-single digits, led by bioproduction, clinical research and the research and safety market channel. Casper said biotech spending improved and began translating into revenue after earlier signs of increased activity. Academic and government revenue grew in the low single digits, driven by chromatography and mass spectrometry. Casper said the market is stabilizing, with strong adoption of new instruments globally and U.S. academic and government revenue returning to growth, though he cautioned that the company is not yet calling it a sustained new trend. Industrial and applied revenue grew in the mid-single digits, led by electron microscopy, chemical analysis and the research and safety market channel. Diagnostics and healthcare also grew in the mid-single digits, driven by the healthcare market channel and immunodiagnostics.

Meyer said all four business segments contributed to the quarter’s performance. In Life Sciences Solutions, reported revenue increased 13%, while organic revenue grew 3%. Growth was led by bioproduction, which Meyer said had another quarter of excellent organic growth. Adjusted operating margin in the segment rose 20 basis points to 37.0%. Analytical Instruments posted 7% growth on both a reported and organic basis. Meyer said all three businesses in the segment grew, led by electron microscopy. Adjusted operating income increased 30%, and adjusted operating margin expanded 420 basis points to 23.0%. Specialty Diagnostics revenue increased 6% on a reported basis and 5% organically. Growth was led by the healthcare market channel, immunodiagnostics and transplant diagnostics. Adjusted o...